Machine learning models can reliably inform clinicians about the disability progression of multiple sclerosis, according to a new study published this week in the open-access journal PLOS Digital ...

An experimental drug can help patients with advanced multiple sclerosis delay the progressive disability that comes with their disorder, a new clinical trial suggests. The drug, tolebrutinib, delayed ...

A pioneering study presented today at ECTRIMS 2024 has identified critical biomarkers that can predict disability worsening in multiple sclerosis (MS). The breakthrough research has the potential to ...

In the field of human rights, growing attention has been devoted to the rights of persons belonging to specific groups, often called "vulnerable groups". People belonging to these groups have certain ...

Neighborhood income and education level is associated with risk of disability progression in patients with multiple sclerosis, suggests new research. Neighbourhood income and education level is ...

Multiple sclerosis (MS) research has uncovered a potential link between certain initial symptoms and long-term disability outcomes. The study, "The association of different acute manifestations of ...

- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...

They also appealed to the government to ensure the full implementation of the law and punish those who discriminate against persons with disabilities in the state. Women with disabilities face ...

A Sanofi experimental drug for multiple sclerosis delayed disability progression in a late-stage trial, but failed to reduce episodes of new or worsening symptoms compared to an existing treatment in ...